Ann: Expanded collaboration with Siemens Healthineers to US, page-111

And heres another thought.
Given the close relationship with Siemens, MRI, and the de-risking as a smart contrast.
If you were Siemens, would you allow the market to once again float this to 200m mc, say, only then have to make a takeover bid significantly higher ?
If you were to wait then, into the phase 2 trials of MRX etc, how much more in valuation do the cheer squad force you to pay ?

Or, do you seize the day, when this is still coming off a heavy discount, priced by the chooks, no longer in the hen house ? And make an early opportunistic bid.?

Can they see the future of molecular imaging ? And what do they do about it ?
Just a thought.